What does ENvue Medical do?
ENvue Medical, Inc. is a commercial-stage medical-device company focused on enteral feeding access. Its strategic product is the ENvue electromagnetic navigation platform, which helps trained clinicians place nasoenteral tubes at the bedside while viewing the path in real time. The system combines a console, reference sensor, software and a proprietary single-use tube with an embedded electromagnetic sensor. The official ENvue System page describes patient registration, airway alerts, movement compensation and three simultaneous views.
Two businesses sit under one public company
The FY2025 Form 10-K reports two segments. NanoVibronix sells PainShield and related acoustic therapeutic products; ENvue sells navigation systems and dedicated feeding tubes. PainShield still generates most revenue, while management’s strategy increasingly centers on navigation, bedside workflow, AI training and robotic assistance.
The official company overview emphasizes safer, more standardized enteral care. For research purposes, ENvue Medical is a commercialization and financing case: a differentiated platform must produce enough hospital utilization and disposable-tube demand to become economically durable.
Its customers include hospital nursing teams, dietitians, physicians, procurement groups and health-system administrators. Each group evaluates a different part of the value proposition: placement guidance, workflow speed, training burden, supply cost, clinical evidence and institutional risk.
How does ENvue Medical make money?
ENvue Medical has two revenue logics. NanoVibronix sells therapeutic devices and recurring treatment kits through direct and distributor channels. ENvue places or sells navigation systems and supplies proprietary disposable tubes used during procedures. As the active installed base grows, repeat tube demand could become the more attractive revenue stream.
PainShield still supplies most reported sales
FY2025 revenue was $2.553 million. NanoVibronix contributed $1.857 million, or 72.7%, while ENvue contributed $696,000, or 27.3%. The mix became even more legacy-weighted in Q1 2026: PainShield and kits represented 82% of quarterly revenue, and ENvue systems and tubes represented 18%. The strategic pivot is therefore ahead of the income statement.
Recurring revenue depends on utilization, not merely installations
A contract creates purchasing access, not guaranteed volume. The commercial conversion is from approval to trained users, protocol adoption and repeat tube consumption. Announced renewals and additional systems show widening access, but the filings still report modest ENvue revenue.
What did the latest quarter show?
The latest filed quarter was materially weaker. The Q1 2026 Form 10-Q reported revenue of $653,000 versus $1.025 million a year earlier. Cost of revenue was $708,000, producing a $55,000 gross loss and a derived negative 8.4% gross margin. Product volume and mix did not absorb manufacturing and inventory costs.
Revenue contraction met a larger commercial expense base
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Revenue | $653,000 | $1.025 million | Down 36% year over year. |
| Gross profit (loss) | $(55,000) | $369,000 | The gross-profit line reversed from positive to negative. |
| Research and development | $468,000 | $530,000 | Down 12%, but still 72% of revenue. |
| Sales and marketing | $772,000 | $349,000 | Up 121% as commercialization investment expanded. |
| General and administrative | $2.416 million | $1.342 million | Up 80%; the largest operating-expense category. |
| Operating loss | $(3.711 million) | $(1.852 million) | Loss doubled as revenue fell and expenses rose. |
| Operating cash flow | $(4.312 million) | $(1.343 million) | Cash use was 6.6 times quarterly revenue. |
Expense intensity explains the financing need
Current assets were $6.197 million against $6.865 million of current liabilities, leaving about $668,000 of negative working capital. Cash fell from $4.224 million at December 31, 2025 to $2.235 million at March 31, 2026. Management again said resources were insufficient for the next 12 months and substantial doubt existed about continued operations.
ENvue Navigation’s hospital-economics thesis
The commercial argument is that bedside navigation can change who performs placements, how quickly feeding begins and how hospitals manage confirmation and complications. Those workflow claims must be supported by repeatable evidence, training and institution-specific protocols before they translate into durable utilization.
Clinical evidence can unlock protocol standardization
The study was announced through the company’s official investor-relations archive. The strategic link is between evidence and procurement: safety and workflow data can reduce institutional resistance, while multi-site standardization can expand tube demand.
Contracts create access; utilization creates economics
Which turning points created today’s strategy?
The useful history is a sequence showing how clearance, commercialization, merger financing and product expansion created today’s opportunity and risk profile.
-
2017The ENvue business was established around electromagnetic navigation rights and enteral-placement technology, creating the platform that later became the strategic center of the public company.
-
February 2019The adult ENvue system received FDA 510(k) clearance for patients age 22 and older, converting the technology from development concept into a regulated commercial product.
-
2020Commercial marketing began. Adoption remained gradual because hospital selling requires clinical validation, purchasing approval, training and workflow change.
-
February 2025ENvue combined with then-NanoVibronix. The $42.452 million acquisition accounting brought the navigation platform into a Nasdaq-listed company but also created substantial goodwill and financing complexity.
-
June 2025Doron Besser became group chief executive, placing a physician-executive at the center of the integration and commercialization effort.
-
January 2026ENFit syringes launched in four sizes, extending the product set toward home, long-term-care and broader enteral-consumable channels.
-
June–July 2026The company introduced Ask Oscar, an AI-based training initiative, and unveiled the investigational ENvue Drive robotic-assistance prototype. These projects expand the platform vision but still require execution, regulatory work and capital.
The merger initially created $39.591 million of goodwill. FY2025 then included $10.509 million of goodwill impairment and $645,000 of intangible impairment. The early write-down means the acquisition narrative must now be validated by revenue growth and cash conversion.
What gives ENvue a competitive position?
Patient-specific navigation and proprietary disposables
ENvue’s main strategic resource is the integrated system: patient registration, reference sensor, proprietary software and a disposable tube with a tip sensor. The company reports 40-image-per-second refresh, airway alerts, movement compensation and three views. Its disclosed tubes include 8 Fr, 10 Fr and 12 Fr sizes, supported by patent families in the United States and other jurisdictions.
Training and protocol validation can create institutional switching friction, but hospitals retain alternative methods. Purchasing still depends on evidence, workflow fit, total cost and competing technologies.
Why the moat is not yet proven
| Approach | Navigation method | Competitive implication | ENvue research question |
|---|---|---|---|
| ENvue | Electromagnetic navigation with dedicated sensor-enabled tube | Integrated platform and recurring consumable; relies on training and proprietary supplies. | Can clinical evidence and account expansion produce durable utilization? |
| Cardinal Health IRIS | Camera-based visualization | Offers a different visualization architecture and large-company distribution resources. | Does ENvue’s navigation workflow offer enough practical differentiation? |
| Avanos CORTRAK 2 | Electromagnetic placement technology | A more directly comparable modality with established market presence. | Can ENvue overcome incumbent relationships and safety scrutiny across the category? |
| Blind placement plus confirmation | Traditional bedside insertion with separate confirmation workflow | Low technology dependence but potentially slower and less informative during insertion. | Will hospitals change protocols enough to justify platform and consumable costs? |
How financially strong is ENvue Medical?
Recorded assets overstate near-term financial flexibility. At March 31, 2026, total assets were $39.871 million, including $29.082 million of goodwill and $4.172 million of intangibles—83.4% of assets combined. Cash was $2.235 million, and current liabilities exceeded current assets.
Annual statements show a financing-dependent model
Goodwill concentration raises impairment sensitivity
| Balance-sheet item | March 31, 2026 | December 31, 2025 | Analytical meaning |
|---|---|---|---|
| Cash | $2.235 million | $4.224 million | Declined as operating burn exceeded financing inflows. |
| Inventory | $2.266 million | $2.337 million | Includes a $122,000 Q1 2026 write-down; inventory quality matters at low volume. |
| Goodwill | $29.082 million | $29.082 million | About 72.9% of Q1 2026 total assets after the FY2025 impairment. |
| Total liabilities | $7.856 million | $7.627 million | Includes a $1.080 million loan and preferred-related obligations. |
| Current ratio | 0.90x | 1.09x | Short-term assets no longer covered short-term liabilities at quarter-end. |
FY2025 revenue was $2.553 million and gross profit only $153,000, versus $1.508 million in FY2024. R&D was $1.762 million, sales and marketing $2.493 million, and G&A $7.633 million. After $11.154 million of impairment, operating loss was $22.889 million and net loss $18.185 million. A $6.204 million non-cash warrant-liability gain reduced net loss, so operating cash flow is the cleaner health measure.
Who owns ENvue stock, and why does governance matter?
Ownership is complicated by preferred securities, conversion rights, warrants, beneficial-ownership caps and equity awards. Common shares outstanding rose from 1,100,413 at December 31, 2025 to 8,695,275 at July 14, 2026, illustrating the dilution used to finance operations and convert preferred claims.
Preferred securities matter more than a simple holder list
| Holder or security | Official filing fact | Source period | Why it matters |
|---|---|---|---|
| Alpha Capital Anstalt | Beneficial-ownership cap of 4.9%; held 39,002 Series X shares, 10,209 Series H shares and 181,344 currently exercisable warrant shares | Preliminary proxy, July 14, 2026 | Economic exposure extends beyond reported common ownership and can create future dilution. |
| Doron Besser | Approximately 2.5% beneficial ownership disclosed in preliminary proxy | July 14, 2026 | CEO incentives are tied partly to equity and fully diluted ownership mechanics. |
| Directors and executive officers as a group | Approximately 2.6% beneficial ownership | July 14, 2026 | Insider common ownership is modest relative to financing stakeholders. |
| Preferred dividend obligations | Q1 2026 dividends included $623,000 for Series X and $236,000 for Series H | Quarter ended March 31, 2026 | Preferred claims increase the gap between net loss and loss attributable to common shareholders. |
The July 2026 preliminary proxy shows that common-share counts can understate potential dilution. Additional warrant and preferred conversion rights remained outstanding, some excluded from beneficial ownership by the 4.9% cap. Per-share analysis therefore requires a scenario-specific fully diluted count.
Board expertise shifted toward clinical operations and finance
A July 14, 2026 Form 8-K reported two resignations, the appointments of Zvi Joseph and Lior Buchman, and Zeev Rotstein’s elevation to chair. New audit, governance and compensation committee assignments matter for a company balancing clinical adoption, AI oversight, financing and controls.
Where could growth come from?
Hospital expansion and same-account deployment
The immediate growth path is deeper use of the cleared ENvue platform: new hospital wins, additional systems within existing networks, nursing-led protocol adoption and more tubes per active system. A July 2026 second-platform deployment at an existing academic center is useful because it indicates expansion after initial customer experience.
AI training, home care and robotic assistance widen the addressable model
Ask Oscar could standardize training and reduce support burden across dispersed hospitals. The official Ask Oscar page positions it as part of the product ecosystem. Successful commercialization could improve onboarding and add service revenue.
ENFit syringes extend the brand into home and long-term enteral care. The January 2026 launch covered 2.5 mL, 5 mL, 10 mL and 60 mL sizes. ENvue Drive combines navigation, AI assistance and robotic motion but remains investigational and not FDA-cleared. Pediatric and vascular extensions are likewise development opportunities, not current revenue streams.
What risks could change the story?
Liquidity, dilution and listing risk are immediate
Funding is the most urgent risk. Recurring losses, negative operating cash flow, negative Q1 2026 working capital and a going-concern warning may require more preferred securities, shares, warrants, loans or strategic capital. Each can add dilution, dividends or refinancing pressure.
Nasdaq compliance is also material. A July 10, 2026 Form 8-K said the bid price stayed below $1.00 for 30 consecutive business days from May 26 through July 8. Prior reverse splits meant no automatic 180-day cure period; the company planned to appeal. Listing uncertainty can weaken financing flexibility.
Regulatory, execution and concentration risks remain structural
| Risk | Official evidence | Financial line affected | What to monitor |
|---|---|---|---|
| Funding and going concern | Q1 2026 cash of $2.235 million and $4.312 million operating cash use | Cash, share count, preferred dividends and interest expense | Financing terms, cash burn and working capital |
| Customer concentration | Top three customers represented 66% of Q1 2026 revenue | Revenue volatility, receivables and inventory | Broader customer mix and repeat orders |
| Regulatory expansion | ENvue Drive is investigational; pediatric and vascular programs require further work | R&D expense, launch timing and future revenue | FDA submissions, clearances and study progress |
| Clinical training and adoption | Hospital use requires trained personnel and protocol integration | Sales productivity and disposable pull-through | Utilization per site and renewal evidence |
| Manufacturing and inventory | Negative gross profit in Q1 2026 and a $122,000 inventory write-down | Gross margin, cash conversion and obsolescence | Unit cost, volume, write-downs and supplier continuity |
| Asset impairment | $11.154 million impairment expense in FY2025 | Book equity and reported operating loss | Market capitalization, forecasts and goodwill testing |
What matters most in a DCF and the final takeaway?
ENvue Medical requires a commercialization-first DCF. The model must fund interim losses and dilution, then estimate installed systems, utilization and disposable pull-through before assuming positive free cash flow. A smooth high-growth forecast without explicit financing would be internally inconsistent.
A DCF is a commercialization and financing model
| Valuation driver | Base evidence | Model implication | Watch item |
|---|---|---|---|
| ENvue installed base | 40th U.S. hospital announced by April 2026, plus multi-site contract access | Build systems by site and deployment timing, not only company-wide revenue growth. | New systems and expansion at existing accounts |
| Tube utilization | Proprietary disposable used with navigated placements | Revenue should equal active systems multiplied by placements and net tube revenue. | Procedures or tubes per active system |
| Gross margin | FY2025 margin about 6%; Q1 2026 gross loss | Model manufacturing absorption and mix before assuming software-like margins. | Segment gross profit and inventory write-downs |
| Operating expense discipline | Q1 2026 operating expenses were $3.656 million on $653,000 revenue | Commercial scaling must eventually grow revenue faster than G&A and selling costs. | Quarterly cash burn and expense growth |
| Financing and dilution | Outstanding common shares rose from 1.100 million to 8.695 million between Dec. 2025 and July 2026 | Value the enterprise first, then divide by a scenario-specific fully diluted share count. | Preferred conversions, warrants and new securities |
| Terminal risk | Small scale, going-concern warning and listing uncertainty | Use explicit probability and discount-rate sensitivity rather than a single smooth forecast. | Liquidity, Nasdaq status and regulatory milestones |
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.